High-yield points
- Biology: SMARCB1 (INI1) loss, rarely SMARCA4. Loss of INI1 staining on IHC is the diagnostic key .
- Three subgroups :
- TYR: infratentorial; youngest.
- SHH: supra- or infratentorial; spans both.
- MYC: supratentorial or spinal; oldest; edema.
- Germline SMARCB1 in about a quarter to a third :
- Prognosis: worse; 2-year OS 7%.
- Inheritance: usually de novo or mosaic.
- Always do germline testing and offer counseling.
- Risk :
- Age under 1 with non-TYR: 5-year OS 0%.
- Age 1 or older with TYR: about 72%.
- Metastatic infants do worst.
- Treatment :
- Approach: maximal safe surgery, intensive chemotherapy (often high-dose with stem cell rescue), and radiotherapy (focal in young children, CSI in older).
- ACNS0333: 4-year OS 43%.
- Extent of resection: its independent value is uncertain.
Landmark papers
- COG ACNS0333 (Reddy et al., J Clin Oncol 2020): 2 induction cycles, 3 cycles of high-dose chemotherapy with stem cell rescue, and involved-field (3D conformal) radiation. 4-year EFS was 37% and OS 43% .
ATRT is an embryonal, CNS WHO grade 4 tumor and one of the most common malignant brain tumors in infants . Its defining genetic event is biallelic inactivation of SMARCB1 (INI1), or rarely of SMARCA4 . Apart from that, the genome is strikingly quiet.
- Historically: a median survival of 6–11 months .
- With intensive multimodal therapy: roughly a third to a half of patients survive long term .
Biology and molecular subgroups
- SMARCB1 loss is essentially the only recurrent event. Whole-genome sequencing of 192 ATRTs found no other recurrent mutations. The subgroups differ epigenetically (in methylation and enhancer landscapes) .
- Three consensus subgroups (international meta-analysis) :
- ATRT-TYR:
- Age: the youngest (median 12 months; 90% under 3 years).
- Location: 75% infratentorial.
- SMARCB1 alteration: mostly deletions.
- Pathways: melanosomal genes (TYR, MITF), BMP and OTX2 upregulated.
- ATRT-SHH:
- Age: intermediate (median 20 months).
- Location: most often supratentorial, and the only subgroup that extends across both compartments.
- SMARCB1 alteration: usually compound heterozygous point mutations.
- Phenotype: neuronally differentiated.
- Two subtypes: SHH-1, mainly supratentorial, and SHH-2, mainly infratentorial.
- ATRT-MYC:
- Age: the oldest (median 27 months).
- Location: 50% supratentorial, and all spinal ATRTs fell in this group.
- SMARCB1 alteration: broad homozygous SMARCB1 deletions.
- Expression: HOXC overexpression.
- Imaging: strong peritumoral edema.
- ATRT-SMARCA4:
- Biology: a separate methylation group .
- Clinical features: associated with more germline mutations, younger age and worse prognosis.
- Earlier transcriptional grouping: ASCL1-positive tumors (supratentorial, now largely SHH) had better 5-year OS: 35% vs. 20% with multimodal therapy .
Germline predisposition (rhabdoid tumor predisposition syndrome)
- Germline SMARCB1 mutation is common :
- Frequency: found in 35% of apparently sporadic rhabdoid tumors.
- Age: median age 6 months, vs. 18 months without.
- Survival: 2-year OS 7% vs. 29%.
- In the EU-RHAB registry :
- Germline mutations: 26%.
- Prognosis: germline status was a negative factor in univariate analysis only.
- Familial risk: usually de novo or germline mosaicism; only 1 of 21 parent pairs carried the mutation. Mosaicism means a real, if low, recurrence risk in siblings, so offer genetic counseling .
- Screen with germline testing of blood, and look for synchronous kidney or soft-tissue rhabdoid tumors .
Prognostic factors
- EU-RHAB (143 patients) :
- Overall outcome: 5-year OS 34.7% and EFS 30.5%.
- Independent risk factors: age under 1 year and a non-TYR signature.
- High risk (under 1 year and non-TYR): 5-year OS 0%.
- Intermediate risk: 32.5%.
- Standard risk (1 year or older and TYR): 71.5%.
- Negative factors in univariate analysis:
- metastatic or synchronous tumors;
- germline mutation;
- incomplete remission;
- omitting radiotherapy.
- St. Jude trials (74 patients) :
- Infants: TYR had the best OS.
- SHH was associated with metastases.
- Children 3 and older, M0 with less than 1.5 cm² of residual tumor: 5-year OS 81.8%.
- Infants with M0 disease: 51.8%.
- Metastatic disease: 25% (children) and 0% (infants).
- Metastases: present in about a third at diagnosis (38% in the Canadian series) .
Surgery
- The evidence on extent of resection is mixed:
- Canadian population-based series (50 patients) :
- GTR improved survival: 2-year OS 60% vs. 21.7%.
- High-dose chemotherapy also helped: 47.9% vs. 27.3%.
- Pooled individual data (332 patients) :
- GTR was not independently significant on multivariate analysis.
- What did help: high-dose chemotherapy (OS HR 0.39) and first-line radiotherapy (OS HR 0.39).
- Meta-analysis (936 patients) :
- Surgery vs. no surgery: median OS 50.3 vs. 28 months.
- Extent of resection: made no significant difference.
- Surgery + RT + chemotherapy: the longest OS (HR 0.48).
- St. Jude: residual under 1.5 cm² defined the best-outcome group in older children .
- Practical reading:
- Pursue maximal safe resection, but don't trade a major deficit for GTR, since the adjuvant therapy carries much of the benefit.
- Hydrocephalus and CSF staging:
- Hydrocephalus is common, especially with posterior fossa tumors.
- Stage with spine MRI and CSF.
- Think ahead about access for intrathecal chemotherapy.
Adjuvant therapy
- COG ACNS0333 (high-dose chemotherapy and focal radiation) :
- Regimen:
- 2 induction cycles;
- 3 cycles of high-dose chemotherapy with stem cell rescue;
- involved-field (3D conformal) radiation.
- Results:
- 4-year EFS 37% and OS 43%.
- Under 36 months: EFS hazard 0.43 vs. historical controls.
- Timing of radiation did not affect survival.
- Relapses: 91% occurred within 2 years.
- Treatment-related deaths: 4.
- Dana-Farber intensive multimodality regimen (IRS-III-based, with intrathecal chemotherapy) :
- Regimen: RT was focal (54 Gy) or craniospinal (36 Gy plus boost).
- Results:
- 2-year PFS 53% and OS 70% in 20 patients.
- Toxicity: radiation recall and transverse myelitis; one toxic death.
- EU-RHAB: anthracycline-based induction, then radiotherapy or high-dose chemotherapy. Omitting radiotherapy predicted worse survival .
- Children 3 and older: craniospinal irradiation plus dose-dense chemotherapy with stem cell rescue. With M0 and minimal residual disease, OS was about 82% .
Related topics
- Embryonal Brain Tumors Beyond Medulloblastoma and ATRT: other embryonal tumors and the breakup of CNS-PNET.
- Medulloblastoma: the other major embryonal tumor, with molecular groups and germline predisposition.
- Ependymoma in Children: another infant posterior fossa tumor with a similar surgical approach.
- Posterior Fossa Tumor Resection: step-by-step procedure.
References
- Johann PD, Erkek S, Zapatka M, et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 2016;29(3):379–393. doi:10.1016/j.ccell.2016.02.001. PMID 26923874. verified
- Ho B, Johann PD, Grabovska Y, et al. Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus. Neuro Oncol 2020;22(5):613–624. doi:10.1093/neuonc/noz235. PMID 31889194. verified
- Holdhof D, Johann PD, Spohn M, et al. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathol 2021;141(2):291–301. doi:10.1007/s00401-020-02250-7. PMID 33331994. verified
- Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol 2009;27(3):385–389. doi:10.1200/JCO.2008.18.7724. PMID 19064966. verified
- Reddy AT, Strother DR, Judkins AR, et al. Efficacy of high-dose chemotherapy and three-dimensional conformal radiation for atypical teratoid/rhabdoid tumor: a report from the Children's Oncology Group trial ACNS0333. J Clin Oncol 2020;38(11):1175–1185. doi:10.1200/JCO.19.01776. PMID 32105509. verified
- Upadhyaya SA, Robinson GW, Onar-Thomas A, et al. Relevance of molecular groups in children with newly diagnosed atypical teratoid rhabdoid tumor: results from prospective St. Jude multi-institutional trials. Clin Cancer Res 2021;27(10):2879–2889. doi:10.1158/1078-0432.CCR-20-4731. PMID 33737307. verified
- Frühwald MC, Hasselblatt M, Nemes K, et al. Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro Oncol 2020;22(7):1006–1017. doi:10.1093/neuonc/noz244. PMID 31883020. verified
- Torchia J, Picard D, Lafay-Cousin L, et al. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. Lancet Oncol 2015;16(5):569–582. doi:10.1016/S1470-2045(15)70114-270114-2). PMID 25882982. verified
- Bourdeaut F, Lequin D, Brugières L, et al. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res 2011;17(1):31–38. doi:10.1158/1078-0432.CCR-10-1795. PMID 21208904. verified
- Lafay-Cousin L, Hawkins C, Carret AS, et al. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. Eur J Cancer 2012;48(3):353–359. doi:10.1016/j.ejca.2011.09.005. PMID 22023887. verified
- Schrey D, Carceller Lechón F, Malietzis G, et al. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. J Neurooncol 2016;126(1):81–90. doi:10.1007/s11060-015-1904-0. PMID 26608522. verified
- Gupta NK, Godbole N, Sanmugananthan P, et al. Management of atypical teratoid/rhabdoid tumors in the pediatric population: a systematic review and meta-analysis. World Neurosurg 2024;181:e504–e515. doi:10.1016/j.wneu.2023.10.089. PMID 37871692. verified
Verification (2026-11-13):
- Each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed.
- Numbers were checked against the PubMed abstracts. The subgroup ages, locations, SMARCB1 alteration types and edema come from the open-access full text of reference 2 (PMC7229260).
- Reference 2's full text gives ATRT-SHH location as 56/68 supratentorial and 30/68 infratentorial, which do not add up. Only the qualitative pattern is stated here.
Caveats:
- The following are standard teaching, not drawn from the cited abstracts:
- "Embryonal, CNS WHO grade 4";
- INI1 immunohistochemistry as the diagnostic key;
- screening for synchronous extracranial rhabdoid tumors;
- the surgical judgment about not trading deficits for GTR.
- All series are small. ACNS0333 compared against historical controls.
- The figure is an original schematic.